Biohaven Ltd. (BHVN)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 274
- Market Cap
- $1.9B
About Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
SentiSense also tracks daily options readings for Biohaven Ltd.: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Biohaven Ltd. stock analysis, sentiment tracking, and market intelligence on SentiSense.